This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kiernan, R. E.
Right arrow Articles by Freed, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiernan, R. E.
Right arrow Articles by Freed, E. O.

 Previous Article  |  Next Article 

Journal of Virology, December 1998, p. 9621-9627, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Cleavage of the Murine Leukemia Virus Transmembrane Env Protein by Human Immunodeficiency Virus Type 1 Protease: Transdominant Inhibition by Matrix Mutations

Rosemary E. Kiernandagger and Eric O. Freed*

Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460

Received 16 July 1998/Accepted 7 September 1998

We have identified mutations in the human immunodeficiency virus type 1 (HIV-1) matrix protein (MA) which block infectivity of virions pseudotyped with murine leukemia virus (MuLV) envelope (Env) glycoproteins without affecting infectivity conferred by HIV-1 Env or vesicular stomatitis virus G glycoproteins. This inhibition is very potent and displays a strong transdominant effect; infectivity is reduced more than 100-fold when wild-type and mutant molecular clones are cotransfected at a 1:1 ratio. This phenomenon is observed with both ecotropic and amphotropic MuLV Env. The MA mutations do not affect the incorporation of MuLV Env into virions. We demonstrate that in HIV-1 virions pseudotyped with MuLV Env, the HIV-1 protease (PR) efficiently catalyzes the cleavage of the p15(E) transmembrane (TM) protein to p12(E). Immunoprecipitation analysis of pseudotyped virions reveals that the mutant MA blocks this HIV-1 PR-mediated cleavage of MuLV TM. Furthermore, the transdominant inhibition exerted by the mutant MA on wild-type infectivity correlates with the relative level of p15(E) cleavage. Consistent with the hypothesis that abrogation of infectivity imposed by the mutant MA is due to inhibition of p15(E) cleavage, mutant virions are significantly more infectious when pseudotyped with a truncated p12(E) form of MuLV Env. These results indicate that HIV-1 Gag sequences can influence the viral PR-mediated processing of the MuLV TM Env protein p15(E). These findings have implications for the development of HIV-1-based retroviral vectors pseudotyped with MuLV Env, since p15(E) cleavage is essential for activating membrane fusion and virus infectivity.

* Corresponding author. Mailing address: Bldg. 4, Rm. 307, NIAID, NIH, Bethesda, MD 20892. Phone: (301) 402-3215. Fax: (301) 402-0226. E-mail: EFreed{at}nih.gov.

dagger Present address: IGH, CNRS-UPR 1142, Montpellier, France.

Journal of Virology, December 1998, p. 9621-9627, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Waheed, A. A., Ablan, S. D., Roser, J. D., Sowder, R. C., Schaffner, C. P., Chertova, E., Freed, E. O. (2007). HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease. Proc. Natl. Acad. Sci. USA 104: 8467-8471 [Abstract] [Full Text]  
  • Stitz, J., Wolfrum, N., Buchholz, C. J., Cichutek, K. (2006). Envelope proteins of spleen necrosis virus form infectious human immunodeficiency virus type 1 pseudotype vector particles, but fail to incorporate upon substitution of the cytoplasmic domain with that of Gibbon ape leukemia virus. J. Gen. Virol. 87: 1577-1581 [Abstract] [Full Text]  
  • Feher, A., Boross, P., Sperka, T., Miklossy, G., Kadas, J., Bagossi, P., Oroszlan, S., Weber, I. T., Tozser, J. (2006). Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.. J. Gen. Virol. 87: 1321-1330 [Abstract] [Full Text]  
  • Potash, M. J., Chao, W., Bentsman, G., Paris, N., Saini, M., Nitkiewicz, J., Belem, P., Sharer, L., Brooks, A. I., Volsky, D. J. (2005). A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc. Natl. Acad. Sci. USA 102: 3760-3765 [Abstract] [Full Text]  
  • Kubo, Y., Amanuma, H. (2003). Mutational analysis of the R peptide cleavage site of Moloney murine leukaemia virus envelope protein. J. Gen. Virol. 84: 2253-2257 [Abstract] [Full Text]  
  • Bobkova, M., Stitz, J., Engelstadter, M., Cichutek, K., Buchholz, C. J. (2002). Identification of R-peptides in envelope proteins of C-type retroviruses. J. Gen. Virol. 83: 2241-2246 [Abstract] [Full Text]  
  • Christodoulopoulos, I., Cannon, P. M. (2001). Sequences in the Cytoplasmic Tail of the Gibbon Ape Leukemia Virus Envelope Protein That Prevent Its Incorporation into Lentivirus Vectors. J. Virol. 75: 4129-4138 [Abstract] [Full Text]  
  • Zeilfelder, U., Bosch, V. (2001). Properties of Wild-Type, C-Terminally Truncated, and Chimeric Maedi-Visna Virus Glycoprotein and Putative Pseudotyping of Retroviral Vector Particles. J. Virol. 75: 548-555 [Abstract] [Full Text]  
  • Halvas, E. K., Svarovskaia, E. S., Freed, E. O., Pathak, V. K. (2000). Wild-Type and YMDD Mutant Murine Leukemia Virus Reverse Transcriptases Are Resistant to 2',3'-Dideoxy-3'-Thiacytidine. J. Virol. 74: 6669-6674 [Abstract] [Full Text]  
  • Kiernan, R. E., Ono, A., Freed, E. O. (1999). Reversion of a Human Immunodeficiency Virus Type 1 Matrix Mutation Affecting Gag Membrane Binding, Endogenous Reverse Transcriptase Activity, and Virus Infectivity. J. Virol. 73: 4728-4737 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»